SeaSpine announced the implantation of the 25,000th NanoMetalene® interbody device, up from 20,000 at the start of 3Q19.
NanoMetalene, a sub-micron layer of titanium that is molecularly bonded to PEEK using atomic fusion deposition, is designed to provide a bone-friendly titanium surface on endplates and throughout graft openings while retaining the benefits associated with PEEK such as biocompatibility, elasticity similar to bone and radiographic visibility.
SeaSpine has expanded NanoMetalene technology throughout its interbody portfolio, including Shoreline® ACS (cervical), Cambria™ (cervical), Hollywood™ (posterior lumbar), Hollywood™ VI (posterior lumbar), Ventura™ (posterior lumbar), Vu aPOD™ Prime (anterior lumbar) and Regatta (lateral lumbar).
“Our proprietary and innovative NanoMetalene surface technology has been, and continues to be, a differentiator in the marketplace,” stated Keith Valentine, President and Chief Executive Officer. “This year alone, NanoMetalene has helped drive U.S. interbody implant revenue at a pace that is six to seven times the market. Our team takes great pride in positively impacting tens of thousands of patients’ lives.”
SeaSpine announced the implantation of the 25,000th NanoMetalene® interbody device, up from 20,000 at the start of 3Q19.
NanoMetalene, a sub-micron layer of titanium that is molecularly bonded to PEEK using atomic fusion deposition, is designed to provide a bone-friendly titanium surface on endplates and throughout graft openings while...
SeaSpine announced the implantation of the 25,000th NanoMetalene® interbody device, up from 20,000 at the start of 3Q19.
NanoMetalene, a sub-micron layer of titanium that is molecularly bonded to PEEK using atomic fusion deposition, is designed to provide a bone-friendly titanium surface on endplates and throughout graft openings while retaining the benefits associated with PEEK such as biocompatibility, elasticity similar to bone and radiographic visibility.
SeaSpine has expanded NanoMetalene technology throughout its interbody portfolio, including Shoreline® ACS (cervical), Cambria™ (cervical), Hollywood™ (posterior lumbar), Hollywood™ VI (posterior lumbar), Ventura™ (posterior lumbar), Vu aPOD™ Prime (anterior lumbar) and Regatta (lateral lumbar).
“Our proprietary and innovative NanoMetalene surface technology has been, and continues to be, a differentiator in the marketplace,” stated Keith Valentine, President and Chief Executive Officer. “This year alone, NanoMetalene has helped drive U.S. interbody implant revenue at a pace that is six to seven times the market. Our team takes great pride in positively impacting tens of thousands of patients’ lives.”
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Copy to clipboard 
